Saturday 17 October 2026
Export SEELQ’s income statement to Excel — free account
Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
0.00
0.00
NaN
Follow SEELQ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — | — | — | 0.00 |
P/S ratio |
— | — | — | 5.75 | — | — | — | 3.07 |
Altman Z-Score |
— | — | — | (14.38) | — | — | — | (96.86) |
Altman Z″-Score (non-manufacturers) |
— | — | — | (34.30) | — | — | — | (243.73) |
P/FCF ratio |
— | — | — | 0.00 | — | — | — | 0.00 |
P/Operating CF |
— | — | — | (5.33) | — | — | — | (3.54) |
P/B ratio |
— | — | — | 0.00 | — | — | — | 0.00 |
Price to Tangible BV |
— | — | — | 0.00 | — | — | — | 0.00 |
EV/Sales |
— | — | — | 3.66 | — | — | — | 2.30 |
EV/EBITDA |
— | — | — | 0.00 | — | — | — | 0.00 |
EV/Operating CF |
— | — | — | (0.90) | — | — | — | (0.21) |
EV/FCF |
— | — | — | (0.90) | — | — | — | (0.21) |
Quick Ratio |
0.18 | 4.00 | 0.01 | 0.95 | 2.11 | 9.50 | 0.62 | 0.10 |
Current Ratio |
0.32 | 4.16 | 0.04 | 1.03 | 2.35 | 10.07 | 0.90 | 0.14 |
Net Debt/EBITDA |
0.15 | 0.60 | 0.01 | 0.34 | 0.45 | 1.12 | 0.10 | 0.09 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 41.69% | 21.43% | 35.98% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 2.84 | 0.31 | (0.77) | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.16 |
Operating CF/Net income |
1.85 | (32.93) | 0.46 | 0.38 | 1.09 | 0.74 | 0.84 | 0.63 |
Capex/Depreciation |
(0.14) | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
(13.91) | (128.61) | (24.31) | (1,025.76) | (114.38) | (38.59) | (5,065.43) | (539.99) |
| 85.14% | (20.41%) | 2,074.63% | 2,175.05% | (1,489.36%) | (220.55%) | (314.84%) | 171.72% | |
| (119.11%) | 5.63% | (100.77%) | (908.21%) | (133.62%) | (130.80%) | (138.42%) | (269.01%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
99.16% | 6.31% | 73.84% | (16,117.92%) | (189.78%) | (87.86%) | 2,960.31% | 113.00% |
Average Days of Receivables |
— | — | — | 0.00 | — | — | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 6,016.80% | 0.00% | 0.00% | 0.00% | 1,367.09% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,015.73% | 0.00% | 0.00% | 0.00% | 571.27% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 122.40% | 0.00% | 0.00% | 0.00% | 181.03% |
Graham Net Nets |
— | — | — | 0.00 | — | — | — | (4.96) |
Graham Number |
— | — | — | 714.56 | — | — | — | 4,399.43 |
Earnings Yield |
— | — | — | (333.92%) | — | — | — | (556.60%) |
Free Cash Flow Yield |
— | — | — | (70.84%) | — | — | — | (353.67%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 70.75 | 0.00 | 0.00 | 0.00 | 57.52 |
Operating CF per Share |
(2.11) | (105,710.00) | (1,976.25) | (3,642.45) | (1,802.84) | (2,076.06) | (2,223.97) | (624.33) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.12) | (105,710.00) | (1,976.25) | (3,642.45) | (1,802.84) | (2,076.06) | (2,223.97) | (624.33) |
Cash per Share |
0.32 | 63,310.00 | 52.50 | 1,936.04 | 1,350.17 | 3,336.19 | 560.76 | 98.15 |
Shareholders Equity per Share |
(1.15) | 43,710.00 | (5,882.50) | (1.32) | 221.72 | 2,428.94 | (383.07) | (874.93) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.15) | 43,710.00 | (5,882.50) | (1.32) | 221.72 | 2,428.94 | (383.07) | (874.93) |
Free Cash Flow |
(13.79) | (10.57) | (1.58) | (19.30) | (20.91) | (48.99) | (61.60) | (23.91) |
Working Capital |
(7.66) | 5.01 | (4.71) | 0.32 | 10.07 | 75.17 | (2.48) | (33.52) |
Capital Expenditures |
(0.01) | — | — | — | — | — | — | — |
Net Current Asset Value |
(8.58) | 4.26 | (4.71) | (0.01) | 2.57 | 57.28 | (10.68) | (33.52) |
EV/EBIT |
— | — | — | 0.00 | — | — | — | 0.00 |
Capex to Sales |
0.00 | — | — | 0.00 | — | — | — | 0.00 |
Price to Operating Income |
— | — | — | 0.00 | — | — | — | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.65 | 1.48 | 0.00 | — | 0.00 | 0.00 | 11.68 | — |
Cash ROIC |
254.10% | (98.78%) | 33.90% | (188.27%) | (81.93%) | (31.83%) | (470.04%) | 80.37% |
Accounts Receivable Turnover |
— | — | — | 0.00 | — | — | — | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | 0.00 | — |
Average Payables |
1.17 | 0.41 | 1.14 | 1.51 | 1.34 | 1.79 | 2.66 | 10.01 |
Average Assets |
6.24 | 5.70 | 3.45 | 5.64 | 14.30 | 50.50 | 53.12 | 14.08 |
Average Common Equity |
(8.73) | (1.57) | (0.17) | (2.36) | 1.28 | 29.95 | 23.36 | (22.06) |
Columns are period end dates